98%
921
2 minutes
20
Background & Objectives: The escalation in carbapenem resistance among Enterobacteriaceae has resulted in a lack of effective therapeutic alternatives. Older antimicrobials, fosfomycin, nitrofurantoin and colistin for urinary tract infections (UTIs) caused by carbapenem-resistant Enterobacteriaceae (CRE) may be effective treatment options. The objectives of this study were to evaluate the utility of fosfomycin, nitrofurantoin and colistin in treating UTI caused by CRE and molecular characterization of the plasmid-mediated carbapenem resistance mechanisms.
Methods: Consecutive, non-duplicate isolates of CR Escherichia coli and Klebsiella spp. from urine cultures were included (n=150). Minimum inhibitory concentrations (MIC) were determined by E-test (fosfomycin and nitrofurantoin) and broth microdilution (colistin). Efficacy ratios were derived by dividing susceptibility breakpoints by observed MIC values of the drugs for the isolates. Isolates were screened for genes coding for carbapenemases using multiplex PCR. Fosfomycin, nitrofurantoin and colistin-resistant isolates were screened for plasmid-borne resistance genes fos A3, oqx AB and mcr-1, respectively using PCR.
Results: Among E. coli, 98.9, 56 and 95 per cent isolates were susceptible to fosfomycin, nitrofurantoin and colistin, respectively, while 94 and 85 per cent of Klebsiella spp. were susceptible to fosfomycin and colistin, respectively. The efficacy ratios indicated fosfomycin as the drug of choice for UTI caused by CR E. coli and Klebsiella spp., followed by colistin. The bla gene was most common, followed by bla. Plasmid-borne genes encoding resistance to fosfomycin, nitrofurantoin and colistin were absent.
Interpretation & Conclusions: With increasing resistance against the current treatment options, older drugs may emerge as effective options. Molecular screening of resistant isolates is essential to prevent the spread of plasmid-borne resistance against these drugs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6563748 | PMC |
http://dx.doi.org/10.4103/ijmr.IJMR_2086_17 | DOI Listing |
IJID Reg
September 2025
Urology Research Center, School of Medicine, Razi Hospital, Guilan University of Medical Sciences, Rasht, Iran.
Objectives: Urinary tract infections caused by multidrug-resistant uropathogenic (UPEC) strains limit therapeutic options and pose a serious threat to global health. This study aimed to analyze the phylogenetic distribution and virulence genes of multidrug resistant (MDR) UPEC strains and their associated risk factors.
Methods: UPEC isolates were subjected to phylogenetic and virulence genotyping using conventional and multiplex polymerase chain reaction methods.
BMJ Open
August 2025
Institut National de Santé Publique du Québec, Quebec, Quebec, Canada.
Objectives: To describe community antibiotic utilisation in Quebec from 2018 to 2022 and to measure the combined impact of the COVID-19 pandemic and of the number of comorbidities on utilisation rates.
Methods: Data from the Quebec Integrated Chronic Disease Surveillance System were used to describe monthly (for the overall antibiotics use) and annual (for the main antibiotic classes) changes in antibiotic utilisation rates from 2018 to 2022, stratified by the number of comorbidities (0, 1, 2 and ≥3) and age group (0-17, 18-64 and ≥65 years old). Poisson regression was used to measure the impact of the pandemic and of comorbidities on antibiotic utilisation rates.
North Clin Istanb
January 2025
Department of Infectious Diseases and Clinical Microbiology, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkiye.
Objective: Urinary tract infections (UTIs) are among the most common bacterial infections. The misuse of antibiotics is one of the factors contributing to the global increase in antimicrobial resistance (AMR), making the management of UTIs more challenging. Our study aims to evaluate the causative agents of UTIs and the factors influencing resistance, as well as to identify antibiotics that can be used in the outpatient treatment of patients diagnosed with UTIs.
View Article and Find Full Text PDFIJID Reg
September 2025
College of Medicine and Health Sciences, Sultan Qaboos University, Seeb, Oman.
Objectives: Rising antimicrobial resistance (AMR) in urinary tract infections (UTI) poses a global challenge. Evidence-based treatment of cystitis requires local resistance data. The DASH to Protect Antibiotics (https://dashuti.
View Article and Find Full Text PDFFront Cell Infect Microbiol
August 2025
Department of Microbiology, JSS Medical College and Hospital, JSS Academy of Higher Education and Research, Mysuru, India.
Introduction: () causes most cases of the urinary tract infections (UTIs) via virulence factors like biofilms. This study identifies key phenotypic and genotypic virulence attributes of Uropathogenic Escherichia coli.
Methodology: A total of 180 uropathogenic (UPEC) isolated from patients with different categories (cystitis, pyelonephritis, recurrent UTI, catheter-associated UTI, and asymptomatic bacteriuria) of UTI and 30 commensal isolated from healthy individuals were evaluated for biofilm production by phenotypic methods using tissue culture plate, tube adherence, and Congo red method, and RT-PCR was used to genetically characterize them.